Xiuning Le

11.0k total citations · 4 hit papers
168 papers, 3.5k citations indexed

About

Xiuning Le is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Xiuning Le has authored 168 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 147 papers in Pulmonary and Respiratory Medicine, 122 papers in Oncology and 28 papers in Molecular Biology. Recurrent topics in Xiuning Le's work include Lung Cancer Treatments and Mutations (140 papers), Lung Cancer Research Studies (48 papers) and Lung Cancer Diagnosis and Treatment (39 papers). Xiuning Le is often cited by papers focused on Lung Cancer Treatments and Mutations (140 papers), Lung Cancer Research Studies (48 papers) and Lung Cancer Diagnosis and Treatment (39 papers). Xiuning Le collaborates with scholars based in United States, Japan and South Korea. Xiuning Le's co-authors include John V. Heymach, Monique B. Nilsson, Tina Cascone, Leonard I. Zon, David M. Langenau, Matthew D. Keefe, Jeffery L. Kutok, Donna Neuberg, Sonia Patel and Jonathan W. Goldman and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Genes & Development.

In The Last Decade

Xiuning Le

159 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy

2022 254 citations Sonia Patel, Monique B. Nilsson et al. Clinical Cancer Research profile →
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC

2020 228 citations Xiuning Le, Monique B. Nilsson et al. Journal of Thoracic Oncology profile →
AI in drug discovery and its clinical relevance

2023 125 citations Rizwan Qureshi, Muhammad Irfan et al. Heliyon profile →
Antibody-drug conjugates in lung cancer: dawn of a new era?

2023 80 citations Niamh Coleman, Timothy A. Yap et al. npj Precision Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xiuning Le United States	32	2.0k	1.8k	1.3k	619	301	168	3.5k
Paul H. Huang United Kingdom	31	1.5k 0.7×	1.5k 0.8×	2.1k 1.6×	701 1.1×	431 1.4×	126	4.2k
Tina Cascone United States	30	1.6k 0.8×	1.8k 1.0×	1.4k 1.1×	684 1.1×	97 0.3×	104	3.4k
George N. Naumov United States	22	1.3k 0.7×	2.3k 1.3×	1.9k 1.5×	1.1k 1.9×	291 1.0×	37	4.0k
Tokuzo Arao Japan	38	1.1k 0.5×	1.4k 0.8×	2.2k 1.7×	771 1.2×	320 1.1×	90	3.7k
Ferdinandos Skoulidis United States	22	1.4k 0.7×	1.8k 1.0×	1.4k 1.1×	729 1.2×	136 0.5×	73	3.1k
Vincenzo Damiano Italy	26	1.2k 0.6×	1.9k 1.0×	1.4k 1.1×	459 0.7×	83 0.3×	62	3.2k
Yoon‐La Choi South Korea	35	930 0.5×	1.6k 0.9×	1.4k 1.1×	1.1k 1.8×	192 0.6×	125	3.7k
Tarek A. Bismar Canada	37	2.6k 1.3×	1.1k 0.6×	2.4k 1.9×	1.3k 2.1×	368 1.2×	129	4.8k
Ximing Tang United States	32	1.6k 0.8×	1.7k 0.9×	1.9k 1.5×	1.0k 1.7×	108 0.4×	70	3.8k
Colin D. Weekes United States	28	634 0.3×	2.1k 1.2×	1.4k 1.1×	758 1.2×	154 0.5×	144	3.5k

Countries citing papers authored by Xiuning Le

Since Specialization

Citations

This map shows the geographic impact of Xiuning Le's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiuning Le with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiuning Le more than expected).

Fields of papers citing papers by Xiuning Le

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiuning Le. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiuning Le. The network helps show where Xiuning Le may publish in the future.

Co-authorship network of co-authors of Xiuning Le

This figure shows the co-authorship network connecting the top 25 collaborators of Xiuning Le. A scholar is included among the top collaborators of Xiuning Le based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiuning Le. Xiuning Le is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Halmos, Balázs, Wade T. Iams, Xiuning Le, et al.. (2025). The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast. Oncology and Therapy. 13(4). 871–880.

Le, Xiuning, Xiaorong Dong, Herbert H. Loong, et al.. (2025). LBA75 Sevabertinib (BAY 2927088) in advanced HER2-mutant non-small cell lung cancer (NSCLC): Results from the SOHO-01 study. Annals of Oncology. 36. S1617–S1617.

Riess, Jonathan W., Adrianus J. de Langen, Santiago Ponce, et al.. (2025). ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib. JCO Precision Oncology. 9(9). e2400818–e2400818. 4 indexed citations

Borgeaud, Maxime, Kaushal Parikh, Giuseppe Luigi Banna, et al.. (2024). Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review. Journal of Thoracic Oncology. 19(7). 973–983. 27 indexed citations

Vokes, Natalie I., Xiuning Le, & Timothy A. Yap. (2024). PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLC. Clinical Cancer Research. 30(18). 3968–3970. 2 indexed citations

Hong, Lingzhi, Sonia Patel, Leylah Drusbosky, et al.. (2024). Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients. npj Precision Oncology. 8(1). 217–217. 11 indexed citations

Wang, Wenjing, et al.. (2024). Targeting the MET gene: unveiling therapeutic opportunities in immunotherapy within the tumor immune microenvironment of non-small cell lung cancer. Therapeutic Advances in Medical Oncology. 16. 12735469–12735469. 3 indexed citations

Concannon, Kyle, et al.. (2023). Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer. Nature Reviews Clinical Oncology. 20(10). 716–732. 22 indexed citations

Cornelissen, Robin, Arsela Prelaj, Sophie Sun, et al.. (2023). Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4). Journal of Thoracic Oncology. 18(8). 1031–1041. 34 indexed citations

10.

Xu, Ting, Ajay Sheshadri, Anita Deswal, et al.. (2023). Comorbidities and Their Impact on Treatment Tolerance and Outcome in Elderly NSCLC Patients Treated with Concurrent Chemoradiation Using Proton or Photon Followed by Immunotherapy. International Journal of Radiation Oncology*Biology*Physics. 117(2). e54–e55. 1 indexed citations

11.

Loong, Herbert H., Gennaro Daniele, Ticiana Leal, et al.. (2023). 1320MO Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a phase I study with BAY 2927088. Annals of Oncology. 34. S761–S762. 4 indexed citations

12.

Viteri, Santiago, Enriqueta Felip, Frank Griesinger, et al.. (2023). 1380P Treatment (Tx) sequencing with tepotinib in previously treated patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION trial. Annals of Oncology. 34. S791–S792. 3 indexed citations

13.

Coleman, Niamh, Kathrina L. Marcelo, Julia F. Hopkins, et al.. (2023). HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma. JCO Precision Oncology. 7(7). e2200211–e2200211. 17 indexed citations

14.

Al-Tashi, Qasem, Maliazurina B. Saad, Amgad Muneer, et al.. (2023). Machine Learning Models for the Identification of Prognostic and Predictive Cancer Biomarkers: A Systematic Review. International Journal of Molecular Sciences. 24(9). 7781–7781. 65 indexed citations

15.

Qureshi, Rizwan, Muhammad Irfan, Taimoor Muzaffar Gondal, et al.. (2023). AI in drug discovery and its clinical relevance. Heliyon. 9(7). e17575–e17575. 125 indexed citations breakdown →

16.

Le, Xiuning, Jacqulyne Robichaux, Monique B. Nilsson, et al.. (2023). 1377P Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity. Annals of Oncology. 34. S790–S790. 2 indexed citations

17.

Wang, Yadong, Zhicheng Huang, Xinyu Liu, et al.. (2022). Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Combination Therapy as First-Line Treatment for Patients with Advanced EGFR-Mutated, Non-Small Cell Lung Cancer: A Systematic Review and Bayesian Network Meta-Analysis. Cancers. 14(19). 4894–4894. 3 indexed citations

18.

Tam, Samantha, Xiaoning Luo, Bonnie S. Glisson, et al.. (2021). Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck. Head & Neck. 43(5). 1592–1603. 3 indexed citations

19.

Le, Xiuning, Pedram Razavi, Daniel J. Treacy, et al.. (2016). Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer. Cancer Discovery. 6(10). 1134–1147. 97 indexed citations

20.

Le, Xiuning, David M. Langenau, Matthew D. Keefe, et al.. (2007). Heat shock-inducible Cre/Lox approaches to induce diverse types of tumors and hyperplasia in transgenic zebrafish. Proceedings of the National Academy of Sciences. 104(22). 9410–9415. 152 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact